search
Back to results

Surgical Staging in Cervical Cancer Prior to Chemoradiation (uterus11)

Primary Purpose

Cervical Cancer

Status
Unknown status
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
lymphadenectomy
Standard Staging
Sponsored by
Charite University, Berlin, Germany
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cervical Cancer focused on measuring Surgical Staging, Cervical Cancer, Chemoradiation, Outcome, Toxicity

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Karnofsky-Index =/> 70,
  • age between 18 - 70 years
  • histological assured cervical cancer (by biopsy)
  • FIGO stages II B - IV
  • written informed consent
  • patient's ability to cooperate

Exclusion Criteria:

  • neuroendocrine tumors or histological mixed types containing neuroendocrine fractions
  • pregnancy, lactation,
  • distant metastases, except paraaortal metastases
  • other malignant diseases in anamnesis
  • pelvic radiotherapy in anamnesis
  • severe internal diseases
  • psychiatric diseases which might query the trial attendance or follow-up
  • HIV-Infection or AIDS
  • drug addiction
  • existing motoric or sensoric polyneuropathy > CTC Grad 1

Sites / Locations

  • Department of Gynaecology, Charité Campus Mitte und Benjamin FranklinRecruiting
  • Department of Radiooncology, Charité Campus Mitte und Campus VirchowRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

operative staging (A)

Standard (B)

Arm Description

operative staging and systemic lymphadenectomy, paraaortal and pelvine, laparoscopic or open

No surgical intervention. Clinical Staging (FIGO) CT Abdomen / pelvic enlarged or suspicious lymphnodes--> CT controlled biopsy and histological analysis.

Outcomes

Primary Outcome Measures

DFS (disease-free survival)

Secondary Outcome Measures

OS, LC, QOL (overall survival, local control,quality of life, the determination of toxicity)

Full Information

First Posted
January 13, 2010
Last Updated
January 14, 2010
Sponsor
Charite University, Berlin, Germany
Collaborators
Deutsche Krebshilfe e.V., Bonn (Germany), Arbeitsgemeinschaft Radiologische Onkologie
search

1. Study Identification

Unique Protocol Identification Number
NCT01049100
Brief Title
Surgical Staging in Cervical Cancer Prior to Chemoradiation
Acronym
uterus11
Official Title
Prospective, Randomised and Multi-centric Therapy Optimisation Study for Examining the Influence of Surgical Staging on the Oncological Results for Patients With Cervix Carcinoma of the FIGO Stages IIB-IV After Chemoradiation
Study Type
Interventional

2. Study Status

Record Verification Date
August 2009
Overall Recruitment Status
Unknown status
Study Start Date
April 2009 (undefined)
Primary Completion Date
April 2013 (Anticipated)
Study Completion Date
April 2017 (Anticipated)

3. Sponsor/Collaborators

Name of the Sponsor
Charite University, Berlin, Germany
Collaborators
Deutsche Krebshilfe e.V., Bonn (Germany), Arbeitsgemeinschaft Radiologische Onkologie

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The aim of this study is to determine whether the modified therapy on the basis of operative staging and systematic, pelvine and paraaortal lymphadenectomy for patients with cervical cancer of the FIGO stages IIB-IV prior to introducing radio-chemotherapy leads to a significant improvement of disease-free survival.
Detailed Description
The aim of this study is to determine whether the modified therapy on the basis of operative staging and systematic, pelvine and paraaortal lymphadenectomy for patients with cervical cancer of the FIGO stages IIB-IV prior to introducing radio-chemotherapy leads to a significant improvement of disease-free survival. To this end, 250 patients with histologically verified cancer of the cervix uteri of the stages IIB-IV shall be randomised to a standard arm (ARM B), whereby the therapy shall be conducted on the basis of the clinical FIGO stage. The patients randomised to the test arm (Arm A), after determining the clinical FIGO stage, shall initially receive an operative staging in the form of a pelvine paraaortal lymphadenectomy (laparoscopic or open). On the basis of the operatively obtained findings, a ("surgically") modified tumour stage shall be determined. This "surgical" tumour stage, which shall take into account the affection of the lymph nodes, the infiltration of the neighbouring organs and the intraperitoneal spread, shall serve as the basis for the execution of primary, combined radio-chemotherapy. The primary end-point is the disease-free survival of both groups, the secondary endpoints are overall survival, the local control of both groups, as well as the determination of toxicity and the quality of life.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cervical Cancer
Keywords
Surgical Staging, Cervical Cancer, Chemoradiation, Outcome, Toxicity

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
250 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
operative staging (A)
Arm Type
Experimental
Arm Description
operative staging and systemic lymphadenectomy, paraaortal and pelvine, laparoscopic or open
Arm Title
Standard (B)
Arm Type
No Intervention
Arm Description
No surgical intervention. Clinical Staging (FIGO) CT Abdomen / pelvic enlarged or suspicious lymphnodes--> CT controlled biopsy and histological analysis.
Intervention Type
Procedure
Intervention Name(s)
lymphadenectomy
Other Intervention Name(s)
debulking, surgical staging
Intervention Description
paraaortal and pelvic lymphadenectomy laparoscopic or open
Intervention Type
Other
Intervention Name(s)
Standard Staging
Other Intervention Name(s)
FIGO Staging
Intervention Description
clinical Staging (FIGO) (examination in narcosis, biopsy, cystoscopy, rectoscopy) X-Ray Radiograph of Thorax, Ultrasound of abdomen, CT abdomen / pelvis positive, suspicious lymphnodes--> CT controlled biopsy
Primary Outcome Measure Information:
Title
DFS (disease-free survival)
Time Frame
4 years
Secondary Outcome Measure Information:
Title
OS, LC, QOL (overall survival, local control,quality of life, the determination of toxicity)
Time Frame
4 years

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Karnofsky-Index =/> 70, age between 18 - 70 years histological assured cervical cancer (by biopsy) FIGO stages II B - IV written informed consent patient's ability to cooperate Exclusion Criteria: neuroendocrine tumors or histological mixed types containing neuroendocrine fractions pregnancy, lactation, distant metastases, except paraaortal metastases other malignant diseases in anamnesis pelvic radiotherapy in anamnesis severe internal diseases psychiatric diseases which might query the trial attendance or follow-up HIV-Infection or AIDS drug addiction existing motoric or sensoric polyneuropathy > CTC Grad 1
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Simone Marnitz, PD
Phone
004930450627162
Email
simone.marnitz@charite.de
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Simone Marnitz, PD
Organizational Affiliation
Department of Radiooncology (Charité Campus Mitte und Virchow), Charitéplatz 1, 10117 Berlin, Germany
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Christhardt Köhler, Prof.
Organizational Affiliation
Department of Gynaecology (Charité Campus Mitte und Benjamin Franklin), Charitéplatz 1, 10117 Berlin, Germany
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Anja Dittgen
Organizational Affiliation
Department of Gynaecology (Charité Campus Mitte), Charitéplatz 1, 10117 Berlin, Germany
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Gynaecology, Charité Campus Mitte und Benjamin Franklin
City
Berlin
ZIP/Postal Code
10117
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christhardt Köhler, Professor
Phone
004930450564091
Email
christhardt.koehler@charite.de
First Name & Middle Initial & Last Name & Degree
Anja Dittgen
Phone
004930450664434
Email
anja.dittgen@charite.de
First Name & Middle Initial & Last Name & Degree
Christhardt Köhler, Professor
First Name & Middle Initial & Last Name & Degree
Anja Dittgen
Facility Name
Department of Radiooncology, Charité Campus Mitte und Campus Virchow
City
Berlin
ZIP/Postal Code
10117
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Simone Marnitz, PD
Phone
004930450527162
Email
simone.marnitz@charite.de
First Name & Middle Initial & Last Name & Degree
Anja Dittgen
Phone
004930450664434
Email
anja.dittgen@charite.de
First Name & Middle Initial & Last Name & Degree
Simone Marnitz, PD
First Name & Middle Initial & Last Name & Degree
Anja Dittgen

12. IPD Sharing Statement

Citations:
PubMed Identifier
17566838
Citation
Sakuragi N. Up-to-date management of lymph node metastasis and the role of tailored lymphadenectomy in cervical cancer. Int J Clin Oncol. 2007 Jun;12(3):165-75. doi: 10.1007/s10147-007-0661-2. Epub 2007 Jun 27.
Results Reference
background
PubMed Identifier
7784021
Citation
Subak LL, Hricak H, Powell CB, Azizi L, Stern JL. Cervical carcinoma: computed tomography and magnetic resonance imaging for preoperative staging. Obstet Gynecol. 1995 Jul;86(1):43-50. doi: 10.1016/0029-7844(95)00109-5.
Results Reference
background
PubMed Identifier
17762920
Citation
Marnitz S, Kohler C, Roth C, Fuller J, Bischoff A, Wendt T, Schneider A, Budach V. Stage-adjusted chemoradiation in cervical cancer after transperitoneal laparoscopic staging. Strahlenther Onkol. 2007 Sep;183(9):473-8. doi: 10.1007/s00066-007-1675-4.
Results Reference
background
PubMed Identifier
10859007
Citation
Bye A, Trope C, Loge JH, Hjermstad M, Kaasa S. Health-related quality of life and occurrence of intestinal side effects after pelvic radiotherapy--evaluation of long-term effects of diagnosis and treatment. Acta Oncol. 2000;39(2):173-80. doi: 10.1080/028418600430734.
Results Reference
background
PubMed Identifier
10924990
Citation
Nag S, Erickson B, Thomadsen B, Orton C, Demanes JD, Petereit D. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):201-11. doi: 10.1016/s0360-3016(00)00497-1.
Results Reference
background
PubMed Identifier
12694671
Citation
Lai CH, Huang KG, Hong JH, Lee CL, Chou HH, Chang TC, Hsueh S, Huang HJ, Ng KK, Tsai CS. Randomized trial of surgical staging (extraperitoneal or laparoscopic) versus clinical staging in locally advanced cervical cancer. Gynecol Oncol. 2003 Apr;89(1):160-7. doi: 10.1016/s0090-8258(03)00064-7.
Results Reference
background
PubMed Identifier
15721408
Citation
Denschlag D, Gabriel B, Mueller-Lantzsch C, Tempfer C, Henne K, Gitsch G, Hasenburg A. Evaluation of patients after extraperitoneal lymph node dissection for cervical cancer. Gynecol Oncol. 2005 Mar;96(3):658-64. doi: 10.1016/j.ygyno.2004.08.053.
Results Reference
background
Links:
URL
http://www.degro.org
Description
Association for Radiooncology

Learn more about this trial

Surgical Staging in Cervical Cancer Prior to Chemoradiation

We'll reach out to this number within 24 hrs